Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib plus standard therapy vs placebo in non-muscle invasive bladder cancer
2006-000687-89Phase 4Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Jul 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in bladder cancer comparing Celecoxib (Onsenal) plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Time to recurrence of transitional cell carcinoma of the bladder. Started Jul 2006; status: completed.
02
Drugs
celecoxib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2006-000687-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000687-89.